Our scRNA‐seq analysis identified VEGFC/KDR as key molecules for ABCP resistance, and in vitro and in vivo models successfully revealed the resistance mechanisms of VEGFC/KDR to anti‐VEGF agents in NSCLC. This evidence concerns the gene VEGFC and non-small cell lung carcinoma.